Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
$0.00
$0.00
$0.05
N/A-2.8213,914 shs5 shs
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
$1.18
+4.0%
$1.03
$0.81
$1.76
$27.79M0.79129,533 shs141,087 shs
ObsEva SA stock logo
OBSV
ObsEva
$0.00
$0.08
$2.14
$7.94M0.688.94 million shs300 shs
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
$1.10
$1.08
$0.59
$8.08
$36.47M0.1701,788 shsN/A
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
$1.54
-1.9%
$1.48
$0.63
$1.91
$179.95M-0.05474,769 shs179,781 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
0.00%0.00%-95.00%-83.33%-99.00%
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
+3.98%-2.89%+24.96%+32.32%-11.65%
ObsEva SA stock logo
OBSV
ObsEva
0.00%0.00%0.00%0.00%0.00%
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
-1.91%-13.48%+8.45%+63.26%+86.67%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
0.6637 of 5 stars
0.01.00.04.50.60.00.0
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
3.2061 of 5 stars
3.75.00.00.00.00.80.6
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/AN/AN/AN/AN/A
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
0.7132 of 5 stars
0.05.00.00.00.61.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
0.00
N/AN/AN/A
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
3.33
Buy$10.00751.06% Upside
ObsEva SA stock logo
OBSV
ObsEva
0.00
N/AN/AN/A
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
0.00
N/AN/AN/A
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ENLV, TLSA, STSA, CALA, and OBSV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/21/2025
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/AN/AN/AN/A
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
N/AN/AN/AN/A$1.00 per shareN/A
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/A$0.41 per shareN/A
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
N/AN/AN/AN/A$1.41 per shareN/A
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
N/AN/AN/AN/A$0.04 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
-$39.65MN/A0.00N/AN/AN/AN/AN/AN/A
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
-$15.01M-$0.66N/AN/AN/AN/A-57.67%-50.52%8/29/2025 (Estimated)
ObsEva SA stock logo
OBSV
ObsEva
-$58.38M-$0.92N/AN/AN/AN/A-416.36%-92.01%N/A
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
-$70.06M-$2.01N/AN/AN/AN/A-115.24%-102.26%N/A
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
-$11.86MN/A0.00N/AN/AN/AN/A8/5/2025 (Estimated)

Latest ENLV, TLSA, STSA, CALA, and OBSV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/30/2025Q1 2025
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
-$0.16-$0.15+$0.01-$0.15N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/AN/AN/A
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
N/AN/AN/AN/AN/A
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/AN/A
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
N/AN/AN/AN/AN/A
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
N/AN/AN/A
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
N/A
7.20
7.20
ObsEva SA stock logo
OBSV
ObsEva
N/A
0.61
0.61
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
N/A
7.44
7.44
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
N/A
1.02
1.02
CompanyEmployeesShares OutstandingFree FloatOptionable
Calithera Biosciences, Inc. stock logo
CALA
Calithera Biosciences
604.87 million4.55 millionNot Optionable
Enlivex Therapeutics Ltd. stock logo
ENLV
Enlivex Therapeutics
7023.65 million20.75 millionOptionable
ObsEva SA stock logo
OBSV
ObsEva
5077.97 million66.74 millionNot Optionable
Satsuma Pharmaceuticals, Inc. stock logo
STSA
Satsuma Pharmaceuticals
2133.15 million22.81 millionNot Optionable
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
8116.85 million70.32 millionOptionable

Recent News About These Companies

Why Tiziana Life Sciences Ltd (TLSA) is Surging in 2025

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Calithera Biosciences stock logo

Calithera Biosciences NASDAQ:CALA

Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

Enlivex Therapeutics stock logo

Enlivex Therapeutics NASDAQ:ENLV

$1.18 +0.05 (+3.98%)
Closing price 07/3/2025 02:39 PM Eastern
Extended Trading
$1.18 0.00 (0.00%)
As of 07/3/2025 04:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

ObsEva stock logo

ObsEva NASDAQ:OBSV

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

Satsuma Pharmaceuticals stock logo

Satsuma Pharmaceuticals NASDAQ:STSA

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Tiziana Life Sciences stock logo

Tiziana Life Sciences NASDAQ:TLSA

$1.54 -0.03 (-1.91%)
As of 07/3/2025 03:23 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.